Journal of Allergy and Clinical Immunology-In Practice最新文献

{"title":"Real-world Effectiveness of Lanadelumab in Hereditary Angioedema: Multi-country INTEGRATED Observational Study.","authors":"Markus Magerl, Laurence Bouillet, Inmaculada Martinez-Saguer, Francois Gavini, Nawal Bent-Ennakhil, Laura Sayegh, Irmgard Andresen","doi":"10.1016/j.jaip.2024.12.008","DOIUrl":"https://doi.org/10.1016/j.jaip.2024.12.008","url":null,"abstract":"<p><strong>Background: </strong>Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of cutaneous or subcutaneous edema. There is clinical need for treatments that reduce the rate of HAE attacks in patients.</p><p><strong>Objectives: </strong>Primary objectives were to evaluate the effectiveness of lanadelumab on attack free rate (AFR; proportion of patients who had zero HAE attacks), and on every two weeks (Q2W) and every four weeks (Q4W) adjustments on AFR.</p><p><strong>Methods: </strong>A retrospective medical chart review study was conducted in 19 HAE centers and included data from HAE type I or II patients treated with lanadelumab (index treatment) in Germany, France, Greece and Austria who were ≥ 12 years of age. Data abstraction occurred 15 September 2021 to 29 June 2022. Analyses were primarily descriptive.</p><p><strong>Results: </strong>Data from 198 patients were collected (61.6% female, 91.9% type I HAE). Lanadelumab treatment patterns varied between countries. Cumulative AFR improved from 0% (pre-index) to 54.4% (12 months post-index) and 39.4% (post-index; median 28.8 months duration). Monthly AFRs varied from 16.2% to 28.3% pre-index (17.7% AFR in the month before index date), and from 82.7% (month 1) to >95% at multiple timepoints between 26- and 43-months post-index. Patients with interval increases (n=144, 72.7%) showed improved cumulative AFR (0% pre-index to 50.0% post-index).</p><p><strong>Conclusions: </strong>This real-world study demonstrates that lanadelumab LTP is effective in improving AFR in HAE type I/II patients on Q2W and dose interval increases. Effectiveness with lanadelumab is rapid and was observed starting from the first month of starting therapy.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Psychosocial Burden of Pediatric Food Allergy in the United States: A Population-Based Survey.","authors":"Melissa L Engel, Christopher M Warren, Linda J Herbert, Andrea A Pappalardo, Ashley Ramos, Ruchi S Gupta","doi":"10.1016/j.jaip.2024.12.007","DOIUrl":"https://doi.org/10.1016/j.jaip.2024.12.007","url":null,"abstract":"<p><strong>Background: </strong>Food allergy (FA) affects approximately one in 12 US children, with prevalence increasing. Aside from considerable health care utilization, accumulating research suggests heightened psychosocial burden among this population.</p><p><strong>Objective: </strong>To characterize FA-related psychosocial burden among a large, nationally representative pediatric sample, and its correlates, including sociodemographic characteristics, comorbid conditions, allergy severity, allergic symptoms, number and type of allergens, and healthcare utilization.</p><p><strong>Methods: </strong>A survey was administered between October 2015 and September 2016 to a nationally representative sample of US households. Survey constructs included the Food Allergy Independent Measure (FAIM), which was developed to quantify adverse impacts of living with FA on psychosocial burden (range = 1-7; higher scores indicate greater burden). FAIM responses were analyzed from caregivers reporting current FA in their child (N = 4734). Linear regression models examined associations with sociodemographic and FA characteristics.</p><p><strong>Results: </strong>The overall estimated mean caregiver-proxy FAIM scores for the US pediatric population were 2.79 (SE = 0.03) for reported FA, 2.96 (SE = 0.04) for convincing FA, and 3.21 (SE = 0.05) for physician-confirmed, convincing FA. Significant differences in caregiver-reported burden (p < .05) were found for sociodemographic (i.e., household income, birth country, child age), and clinical (i.e., FA severity, physician diagnosis, specific allergens) factors.</p><p><strong>Conclusion: </strong>While heterogenous to a degree, the psychosocial burden of children with FA was substantial irrespective of sociodemographic and clinical characteristics. FAIM norms can be used clinically, as well as be leveraged by other economic, epidemiological, and health efforts to understand the public health impact of FA.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of food allergy: Immunotherapy, omalizumab, or both.","authors":"Helen A Brough, Edwin H Kim, Aikaterini Anagnostou, Bruce J Lanser, R Sharon Chinthrajah, Sayantani B Sindher","doi":"10.1016/j.jaip.2024.12.011","DOIUrl":"https://doi.org/10.1016/j.jaip.2024.12.011","url":null,"abstract":"<p><p>Food allergy is a common disease which has substantial impacts on the quality of life of patients and their families, and all reactions have the potential for causing life-threatening anaphylaxis. Food allergic individuals currently have 2 FDA approved therapeutic options available to them aside from life-long allergen avoidance: oral immunotherapy (OIT), and omalizumab. OIT for food allergy has been extensively studied in clinical trials and currently provides the greatest level of protection, however it also has a high burden of treatment. Studies suggest that more successful OIT outcomes may be attained with earlier intervention; however, early OIT presents its own challenges. Omalizumab, recently FDA-approved, is a biologic targeting immunoglobulin E, a major driver of allergic reactions. In contrast to OIT, omalizumab monotherapy offers a low treatment burden therapeutic option that provides a safety net against reactions to accidental ingestion to multiple allergens. Additionally, omalizumab has also been investigated as an adjunct to OIT, improving the speed and safety of single or multi-allergen OIT. Here we discuss the clinical use of these therapeutic options and provide a guide for shared decision-making between patients and physicians about what therapeutic option might be more appropriate.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-pharmacological approaches to chronic cough.","authors":"Anne E Vertigan, Jemma Haines","doi":"10.1016/j.jaip.2024.12.012","DOIUrl":"https://doi.org/10.1016/j.jaip.2024.12.012","url":null,"abstract":"<p><p>While cough is a protective reflex it can occur in the absence of any physical need to clear the airway. In chronic cough, cough can be triggered by innocuous stimuli and persist despite medical treatment. Non-pharmacological interventions such as cough control therapy, provided by speech pathologists, have gained popularity in recent years. Intervention targets refractory or unexplained chronic cough and efficacy has been studied in randomised controlled trials. Key elements of cough control therapy include education, anticipation and control of the urge to cough, reducing laryngeal irritation and psychoeducational counselling. Our understanding of the mechanisms behind the success of non-pharmacological treatment is developing. It is likely the mechanisms of action are multi-factorial across peripheral, central and higher cortical regions. Non-pharmacological cough control therapy interventions are now included in international cough guidelines. However, approach to service delivery is not standardised and varies between regions and countries.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of oral immunotherapy for egg allergy according to age of therapy commencement.","authors":"Melanie Lloyd, Jedidiah I Morton, Rachel L Peters, Paxton Loke, Sarah Ashley, Marcus S Shaker, Matthew Greenhawt, Zanfina Ademi, Mimi Lk Tang","doi":"10.1016/j.jaip.2024.12.005","DOIUrl":"https://doi.org/10.1016/j.jaip.2024.12.005","url":null,"abstract":"<p><strong>Background: </strong>Egg oral immunotherapy can induce desensitization or remission of egg allergy in children.</p><p><strong>Objective: </strong>To determine the cost-effectiveness of OIT for raw egg allergy in school-aged children compared to egg avoidance, and the most cost-effective age at which to commence treatment.</p><p><strong>Methods: </strong>A decision-analytic Markov model estimated the health and cost outcomes of 1000 children aged four years with egg allergy, comparing different ages of OIT commencement (from ages 4-12, inclusive) versus ongoing egg avoidance. Years lived with egg allergy, egg tolerance/remission (natural and OIT-induced) and desensitization to egg were captured, with rates of allergic reactions and utility values assigned to each health state. Treatment effects were derived from published randomized clinical trials and meta-analyses. The main outcome was incremental cost effectiveness ratio (ICER) from the Australian healthcare payer perspective (costs in AU$ per quality-adjusted life year [QALY] gained), with a 20-year time horizon, 5% annual discounting and an AU$50,000/QALY willingness-to-pay (WTP) threshold.</p><p><strong>Results: </strong>Without OIT, n=858 attained natural resolution before age 24. Under conservative assumptions, with OIT-induced remission set at zero and 84% achieving desensitization, ICERs were below the WTP threshold for treatment commencement ages ≥8, with the smallest ICER observed at age 12 (AU$43,233/QALY [95% CI: 32,025-73,350]). However, cost-effectiveness of OIT was achieved at all ages (ICER<WTP threshold) if OIT-induced remission increased to ∼40% of treated children.</p><p><strong>Conclusions: </strong>Based on current published evidence, cost-effectiveness of egg OIT improves with increased age of treatment commencement. Cost-effectiveness increases when the proportion of children achieving OIT-induced remission increases.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Piperacillin Lymphocyte Transformation Testing in Patients With Cystic Fibrosis Receiving Regular and Desensitization Courses of Piperacillin-Tazobactam.","authors":"Paul Whitaker, Andrew Gibson, John Farrell, Lindsey Gillgrass, Xiaoli Meng, Daniel Peckham, Dean John Naisbitt","doi":"10.1016/j.jaip.2024.12.003","DOIUrl":"10.1016/j.jaip.2024.12.003","url":null,"abstract":"<p><strong>Background: </strong>Piperacillin-tazobactam is used in patients with cystic fibrosis to treat recurrent respiratory infections. Exposure is associated with a high frequency of nonimmediate hypersensitivity.</p><p><strong>Objective: </strong>To assess the applicability of the lymphocyte transformation test (LTT) for the diagnosis of piperacillin hypersensitivity and the influence of desensitization on piperacillin-specific T-cell responses.</p><p><strong>Methods: </strong>Study arm 1 was an analysis of LTT responses from 58 naive/baseline tolerant patients with samples collected over a 3-year interventional phase. In study arm 2, 17 hypersensitive patients were recruited and LTTs were conducted before and after desensitization. Clinical hypersensitivity reactions in both arms were monitored over an 8-year observational period.</p><p><strong>Results: </strong>In study arm 1, 58 patients received 611 piperacillin-tazobactam courses (range, 2-40; mean ± SD, 10.5 ± 8.1) during the interventional phase; 11 patients developed hypersensitivity. The patients who remained tolerant received 236 piperacillin-tazobactam courses in the observational period, 9 of whom developed hypersensitivity. Ten of 11 interventional phase hypersensitive patients had a positive LTT whereas one remained negative. We recorded 136 negative LTTs with 39 tolerant patients, whereas eight patients had a positive LTT and four developed hypersensitivity during the observational period. Ten LTT-positive patients in study arm 2 underwent piperacillin-tazobactam desensitization, with seven tolerating the drug. The strength of the LTT decreased during desensitization, and negative results were recorded for a minimum of 14 days. During follow-up, eight patients tolerated 62 piperacillin-tazobactam courses through desensitization.</p><p><strong>Conclusions: </strong>The LTT is a sensitive marker of drug sensitization that could be used to inform future patient management. Desensitization is associated with attenuation of the piperacillin-specific T-cell response.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study.","authors":"Alexandre Beyrouti, Juliette Deuze, Eric Fontas, Aurore Foureau, Sébastien Barbarot, Hélène Aubert, Claire Bernier, Marie Le Moigne, Thierry Passeron, Feriel Boukari, Margaux Garnier, Marie Jachiet, Florence Tetart, Julien Seneschal, Clémentine Toussaint, Emmanuel Mahé, Camille Leleu, Marie Masson Regnault, Justine Pasteur, Audrey Nosbaum, Antoine Badaoui, Anne-Claire Fougerousse, Pauline Pralong, Manuelle Viguier, Catherine Droitcourt, Claire Abasq, Stéphanie Mallet, Nadia Raison-Peyron, Delphine Staumont-Sallé, Thomas Hubiche","doi":"10.1016/j.jaip.2024.12.001","DOIUrl":"10.1016/j.jaip.2024.12.001","url":null,"abstract":"<p><strong>Background: </strong>Patients with atopic dermatitis (AD) may discontinue dupilumab owing to dupilumab-induced ocular adverse events (DOAEs) or dupilumab-induced facial redness (DFR).</p><p><strong>Objective: </strong>To evaluate DOAE and DFR outcomes after switching to tralokinumab or Janus kinase inhibitor (JAKi).</p><p><strong>Methods: </strong>This retrospective study included 106 patients discontinuing dupilumab because of DOAEs and/or DFR. The primary outcome was the proportion of patients with resolution of adverse events or improvement between dupilumab discontinuation (M0) and 3 to 6 months of tralokinumab or JAKi (M3-M6) treatment; the secondary outcome was the percentage of patients with controlled AD defined by Investigator's Global Assessment scores of 0/1 at M3 to M6.</p><p><strong>Results: </strong>Proportions of patients with DOAE (92% vs 72%; P = .0244) and DFR (85% vs 33%; P = .0006) resolution or improvement were higher with JAKi than with tralokinumab. Proportions of patients reaching an Investigator's Global Assessment score of 0/1 increased from M0-M3 through M6 (22% vs 42%; P = .0067) in the JAKi group and remained similar (32% vs 35%) in the tralokinumab group. However, 57% discontinued the new treatment after 8 months on average, mainly owing to lack of efficacy.</p><p><strong>Conclusions: </strong>Janus kinase inhibitor appears to be more efficient than tralokinumab in managing dupilumab-induced AE; however, both strategies may fail to control AD.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Wildfires on Asthma and Allergies.","authors":"John R Balmes, Anne Hicks, Mary M Johnson, Kari C Nadeau","doi":"10.1016/j.jaip.2024.12.004","DOIUrl":"10.1016/j.jaip.2024.12.004","url":null,"abstract":"<p><p>Climate change is a major driver of the frequency and severity of wildfires caused by extended periods of drought and hotter, drier weather superimposed on the legacy of fire suppression in the Mountain West of the United States. In recent years, increased wildfire smoke has negated the improvements in air quality made by clean energy transitions. Wildfire smoke is a complex mixture of gases and solids, a chief constituent of which is fine particulate matter (PM_2.5). Exposure to PM_2.5 is associated with adverse respiratory outcomes, including exacerbations of asthma and chronic obstructive pulmonary disease. In the face of increasing wildfire smoke exposures, it is critical that adaptation and mitigation strategies be put in place to minimize health effects. Individual strategies include modifying behavior and creating clean air spaces in homes to avoid wildfire smoke exposure. Community strategies include regulations promoting fire-resistant buildings and landscaping; establishing wildfire monitoring and alert systems; providing safe clean spaces where individuals can minimize wildfire smoke exposure and find evacuation routes; and creating health care response teams. Mitigation to prevent wildfires includes forest management and establishing monitoring systems and protocols to control forest fires in the wildland urban interface before they increase in size and intensity. Research into understanding the mechanism by which wildfire smoke mediates adverse health effects can inform guidelines to mitigate its health effects further.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common Variable Immunodeficiency Clinical Manifestations Are Shaped by Presence and Type of Heterozygous NFKB1 Variants.","authors":"Jie Yin, Kevin M Hayes, Mei-Sing Ong, Joseph P Mizgerd, Charlotte Cunningham-Rundles, Isabel Dominguez, Sara Barmettler, Jocelyn R Farmer, Paul J Maglione","doi":"10.1016/j.jaip.2024.12.002","DOIUrl":"10.1016/j.jaip.2024.12.002","url":null,"abstract":"<p><strong>Background: </strong>NFKB1 encodes p105, which is processed to p50 to mediate canonical nuclear factor-κB (NF-κB) signaling. Although NF-κB is a central driver of inflammation and heterozygous NFKB1 variants are considered the most common monogenic etiologies of common variable immunodeficiency (CVID), few studies have explored how NFKB1 variants shape clinical course or inflammation in CVID.</p><p><strong>Objective: </strong>We leveraged a regional cohort of patients with CVID with and without heterozygous NFKB1 variants to assess how clinical and inflammatory features of CVID are shaped by the presence of these variants.</p><p><strong>Methods: </strong>We compared clinical complications, immunologic features, and plasma cytokine levels of 15 patients with CVID with heterozygous NFKB1 variants and 77 genetically undefined patients with CVID from the same referral base. We also assessed differences between patients with CVID with frameshift or nonsense NFKB1 variants compared with those with missense NFKB1 variants.</p><p><strong>Results: </strong>We found patients with CVID with heterozygous NFKB1 variants to have increased autoimmune disease, bronchiectasis, gastrointestinal infections, inflammatory bowel disease, and plasma cytokines. These findings were more pronounced and included elevation of monocytes in patients with CVID with frameshift or nonsense NFKB1 variants relative to those with missense NFKB1 variants.</p><p><strong>Conclusions: </strong>In a regional cohort, heterozygous NFKB1 variants were associated with worsened CVID clinical course and increased evidence of inflammation in the blood. Patients with CVID with frameshift or nonsense NFKB1 variants had more significant increases in noninfectious complications and peripheral monocytes than those with missense NFKB1 variants. Presence of pathogenic NFKB1 variants in patients with CVID may worsen the disease course and warrant closer monitoring.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of serum IL-18 levels for the follow-up of patients with familial Mediterranean fever.","authors":"Inès Elhani, Laure Calas, Farah Bejar, Laurence Pieroni, Isabelle Kone-Paut, Linda Rossi-Semerano, Isabelle Melki, Brigitte Bader-Meunier, Bénédicte Neven, Pierre Quartier, Guilaine Boursier, Irina Giurgea, Laurence Cuisset, Gilles Grateau, Véronique Hentgen, Philippe Mertz, Marion Delplanque, Léa Savey, Sophie Georgin-Lavialle","doi":"10.1016/j.jaip.2024.11.025","DOIUrl":"10.1016/j.jaip.2024.11.025","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}